French biotech company Ziwig has secured fast-track reimbursement for its Ziwig Endotest, making the saliva-based endometriosis diagnostic test available to 25,000 patients across 80 medical centers in France. The reimbursement comes through an Innovation Funding decree issued February 11.
The Ziwig Endotest has shown 97.4% sensitivity and 93.5% specificity in detecting all forms of endometriosis, including early peritoneal endometriosis. This non-invasive diagnostic tool provides results within days and aims to address the significant diagnostic delay faced by endometriosis patients, which currently ranges from 7 to 10 years.
“With Ziwig Endotest we are determined to end the unacceptable diagnostic wandering that leaves many women in pain. The coverage of Ziwig Endotest in 80 centers in France, with early access made possible by the French health authorities, is a breakthrough for patients and doctors,” said Yahya El Mir, CEO-Founder of Ziwig.
The test is already available on prescription in multiple countries including Germany, Switzerland, Italy, United Kingdom, and several Nordic and Middle Eastern nations. Expansion plans include upcoming availability in India, Romania, and Brazil.
Ziwig, which received the 2024 Galien International Prize and support from France 2030 plan, is also exploring how salivary RNA and AI can be used to diagnose other conditions, including ovarian adnexal masses and amyotrophic lateral sclerosis (ALS). The Innovation Funding provides early access to innovative technologies that address unmet medical needs or reduce medical expenses toward mainstream healthcare coverage.
